Compugen Extends Financial Runway to 2029 on Strong Revenue, Navigates Clinical Trial Timelines
This analysis is based on the company's Q4 2025 earnings call and financial report.
HERZLIYA, Israel – March 2, 2026 – Compugen Ltd. (NASDAQ: CGEN) closed its fiscal year with a significant revenue surge, the company announced Monday, bolstering its cash position and extending its financial runway well into 2029. The strengthened balance sheet provides a multi-year cushion as the clinical-stage biotech navigates the complex development paths for its pipeline of cancer immunotherapies, including partnered assets with AstraZeneca and Gilead.
While the core financial news was positive, management provided updated timelines for several key clinical trials, notably pushing an interim analysis for an ovarian cancer study into the first quarter of 2027. CEO Eran Ophir attributed the shift to slower-than-expected activation of major U.S. academic trial sites, though he confirmed all are now operational.
"The current trial for COM701 employs an adaptive design, and we anticipate data maturation in Q1 2027," said Chief Medical Officer Michelle Mahler, responding to analyst inquiries. "The subsequent path to regulatory submission will be dictated by the totality of that data. We are planning for success and considering follow-on studies."
On the partnership front, CFO David Silberman highlighted the remaining value in the company's deal with AstraZeneca for the dual immunotherapy rilvegostomig. "Our next milestone will be Biologics License Application (BLA) acceptance, triggering a $25 million payment," Silberman noted. "In total, we remain entitled to up to $195 million in potential milestone payments from AstraZeneca for this asset alone." The partner recently initiated an 11th Phase 3 trial for the drug, this time in gastric cancer.
Separately, Compugen retains full rights to COM902, a TIGIT antibody seen as a cornerstone for future multi-specific drug constructs and potential new collaborations.
Market and Analyst Reaction:
The extended cash runway was widely viewed as a critical de-risking event, allowing Compugen to fund operations through multiple anticipated data readouts without immediate dilution. However, the timeline adjustments underscore the inherent volatility of late-stage clinical development.
Dr. Anya Sharma, Portfolio Manager at BioVenture Capital: "The runway extension to 2029 is a masterclass in financial discipline. It removes the 'when will they need cash?' overhang and lets the market focus purely on clinical data, starting with the 2027 readouts. This positions them as a patient, data-driven story."
Michael Torrence, Independent Biotech Analyst: "Another delay, another 'site activation' excuse. While the cash news is good, investors are right to be frustrated. The ovarian trial timeline slip is meaningful, and the market's patience for '2027 data' narratives is wearing thin. They need to execute on these revised timelines without further slippage."
Sarah Chen, PhD, Oncology Research Specialist: "The continued expansion of rilvegostomig into an 11th Phase 3 trial by AstraZeneca is a powerful external validation of the asset's potential. It speaks volumes about the compound's profile that a pharma giant is investing so heavily across so many tumor types."
David Klein, Private Investor: "The distinction between the partnered TIGIT (rilvegostomig) and their wholly-owned COM902 is crucial. It shows they're not a one-trick pony. COM902 is their future deal-making engine, and the strong cash position means they don't have to partner it prematurely."
For a full transcript of the earnings call, please visit the investor relations section of the Compugen website.